All companies
Visit website
Covira Surgical (Biotech)
OperatingCovira Surgical, Inc.
Healthcare · Biotech · Founded 2018
Revolutionizing Surgical Infection Prevention
Post-money valuation ⓘ
$11.0M
As of Apr 2022 · from Covira Surgical Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$596,509
Across 1 round since 2021
Latest share price
$1.00
Covira Surgical Common Stock 1 offering price
Financials
FY2019–FY2023 · from SEC filings · hover any figure for its source$0
−$53K
2019
$0
−$39K
2020
$0
−$231K
2021
$0
−$367K
2022
$283K
−$361K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$0
$0
$0
$282,875
Cost of goods sold
$0
$0
$0
$0
$0
Gross margin
—
—
—
—
100%
Net income
-$52,678
-$38,932
-$230,809
-$367,317
-$360,719
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$4,132
$118,858
$153,578
$581,973
$95,971
Accounts receivable
$0
$0
$21,206
$7,000
$0
Total assets
$4,132
$118,858
$174,784
$683,473
$321,647
Short-term debt
$58,814
$212,016
$1,615
$0
$0
Long-term debt
$0
$0
$0
$199,000
$199,000
Total liabilities
$58,814
$212,016
$1,615
$199,000
$199,000
Other
Headcount
—
8
2
8
8
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$11.0M
post-money
Covira Surgical Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $596.5K / $1.1MInvestors 526Post-money $11M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 3 of 5 annual reports (FY2021–FY2025)
526 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGARSource: ManualCIK 0001857825Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.